Request Demo
Last update 08 May 2025
Factor VIII(China Resources Boya Bio-Pharmaceutical Group)
Last update 08 May 2025
Overview
Basic Info
Drug Type Non-recombinant coagulation factor |
Synonyms- |
Target |
Action stimulants |
Mechanism F10 stimulants(Coagulation factor X stimulants), Coagulation factor VIII replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (08 Aug 2022), |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Factor VIII(China Resources Boya Bio-Pharmaceutical Group)CTR20241567
评价人凝血因子Ⅷ在重型血友病A（因子Ⅷ缺乏症）患者中单次给药后安全性和药代动力学特征的单臂、开放、单中心临床试验
[Translation] A single-arm, open-label, single-center clinical trial to evaluate the safety and pharmacokinetic characteristics of human coagulation factor VIII after a single dose in patients with severe hemophilia A (factor VIII deficiency)
CTR20192501
人凝血因子Ⅷ治疗甲型血友病患者的疗效及安全性的多中心、开放性临床研究
[Translation] A multicenter, open-label clinical study on the efficacy and safety of human coagulation factor VIII in the treatment of hemophilia A patients
CTR20150652
人凝血因子Ⅷ治疗甲型血友病患者的疗效及安全性的 多中心、开放性临床研究
[Translation] A multicenter, open-label clinical study on the efficacy and safety of human coagulation factor VIII in the treatment of hemophilia A patients
100 Clinical Results associated with Factor VIII(China Resources Boya Bio-Pharmaceutical Group)
Login to view more data
100 Translational Medicine associated with Factor VIII(China Resources Boya Bio-Pharmaceutical Group)
Login to view more data
100 Patents (Medical) associated with Factor VIII(China Resources Boya Bio-Pharmaceutical Group)
Login to view more data
100 Deals associated with Factor VIII(China Resources Boya Bio-Pharmaceutical Group)
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hemophilia A | China | 08 Aug 2022 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemorrhage | Discovery | China | 07 Mar 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free